A health worker samples an RT-PCR swab test for diagnosis of Kovid-19 at Katraj Center in Pune on Monday. (Express photo by Pavan Khengre) On Sunday, the Center wrote to five states reporting an increase in cases to implement a multi-pronged strategy to curb the spread of Kovid-19. While India’s cumulative positivity rate was 5.20 percent on Sunday, the Health Ministry said the country’s national average weekly positivity rate was 1.79 percent. Hyderabad-headquartered vaccine manufacturer Bharat Biotech expects the company’s chairman and managing director, Dr. According to Krishna Ella, interim data on the efficacy of covaxin will be available in the next two weeks. This will be the first time the company will be able to provide clarity on how many symptomatic cases of Kovid-19’s indigenous vaccine prevention. Kovaxin received a restricted use approval in an emergency from the Drug Controller General of India on 3 January. However, since Bharat Biotech had not recruited and completed vaccination enough participants for Phase 3 trials, the approval was without efficacy data. The government said the approval was “in the public interest”, as it was believed that the vaccine, which contains killed virus particles, would be more effective against mutant strains. Bharat Biotech first reviewed data on the ability of covaxin to protect non-peers from UK stress. According to Ella, the company can modify kovaxine within 15 days of receiving the South African strain against which other vaccines, such as Kovishield, have so far not been effective. .